You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Optimizing Small Molecule Mechanomimetics to Treat Age-related Osteoporosis.

    SBC: OAK RIDGE THERAPEUTIC DISCOVERY LLC            Topic: NIA

    Abstract There is an unmet need to develop treatments for senile osteoporosis, a disorder characterized by an age-related reciprocal decrease in osteogenesis and increase in bone marrow fat. Senile osteoporosis resembles disuse osteopenia, suggesting its pathogenesis involves impaired bone mechanosensing. We discovered that the polycystin heterotrimeric complex (1PC1+3PC2) functions as a mechanose ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Developing a selective TRPC3 ion channel inhibitor for epilepsy treatment

    SBC: SEAK Therapeutics, LLC            Topic: 106

    Project SummaryEpilepsy is one of the most common brain disorders. Current drugs have limited efficacy. Identifying new targeted drugs that can be used as safer, more effective therapies is in urgent unmet need. Selective inhibition of the transient receptor potential canonical 3 (TRPC3) emerges as a novel strategy to impede epilepsy. However, the currently best selective TRPC3 inhibitor, Pyr3, ha ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Precision Guidance of Resuscitation and Deresuscitation in Sepsis

    SBC: DAXOR CORPORATION            Topic: 300

    ABSTRACT Sepsis impacts 1.7 million Americans annually, leading to 270,000 deaths and $62 billion in costs. Most of the sepsis treatment follows the Surviving Sepsis Campaign (SSC) guidelines, consisting of early antibiotics, liberal fluid resuscitation, and vasopressor use in persistent hypotension. However, the fundamental assumption that sepsis universally results in high capillary leak leading ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a novel depot delivery system for a glaucoma therapeutic

    SBC: OCULO THERAPY LLC            Topic: NEI

    Glaucoma is the leading cause of irreversible blindness in the world. Because elevated intraocular pressure (IOP) and IOP fluctuations are the primary risk factors for loss of visual field, the current standard of care for adult-onset glaucoma includes treatment with IOP-lowering medications, which are typically delivered topically as eye drops. Unfortunately, the need for self-administration nega ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Educational Leadership Virtual Practicum System

    SBC: Pragmatic Solutions, Inc.            Topic: 91990022R0001

    Not available

    SBIR Phase I 2022 Department of EducationInstitute of Education Sciences
  6. Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage

    SBC: VasaMetrix            Topic: 107

    PROJECT SUMMARYSubarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm leads to delayed vasospasm resulting in neuroischemia (stroke). The overall morbidity (profound neurologic deficit in 10-20% of survivors) and mortality (50%) are high, and the disease affects a relatively young adult population. Therapeutic options to prevent delayed vasospasm and neuroischemia after SAH are c ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Label-free, Multimodality Diffuse Reflectance and Polarization-Based Proximity Probe for Iatrogenic Nerve Injury Prevention During Surgical Procedures

    SBC: YAYA SCIENTIFIC LLC            Topic: NIBIB

    PROJECT SUMMARY We propose to develop a novel contact, label-free multimodality-based sensing probe that provides real-time intraoperative identification of nerves within the thermal damage threshold range of a surgical tool. The tool will facilitate prevention of direct/indirect nerve damage (termed iatrogenic nerve injury) during surgical procedures, as they are a major source of postsurgical co ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Assessment of a Microprocessor Ankle for Low Mobility Individuals with Amputation

    SBC: Synchro Motion LLC            Topic: NICHD

    PROJECT SUMMARYMicroprocessor-controlled ankles have been shown to substantially improve mobility and stability in individuals with lower limb amputation, but these devices are typically only available to higher mobility users due to a lack of scientific evidence to justify insurance reimbursement. As such, many of the individuals with lower limb amputation that have the greatest need for advanced ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a molecular-level skin condition diagnostic for precision medicine

    SBC: Finally, LLC            Topic: NIAMS

    PROJECT SUMMARY The American Academy of Dermatology reports that 1 in 4 Americans (~84.5 million) are impacted by skin disease. Skin disease is the fourth leading cause of disability worldwide, significantly impacts quality of life, and costs ~$75 billion annually to treat. Skin conditions like atopic dermatitis (AD) are commonly diagnosed by practitioners using clinical history and physical exam ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis

    SBC: DECODE HEALTH, INC.            Topic: r

    PROJECT SUMMARYDiagnosis and monitoring of multiple sclerosis (MS) rests on clinical symptoms and examinations as outlined in the revised McDonald criteria. These criteria are supported by appropriate magnetic resonance imaging (MRI) findings or other laboratory tests such as detection of oligoclonal bands in cerebrospinal fluid and evoked potential testing.(1-7) Approximately 10,000-15,000 new di ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government